Wenxin Zheng, M.D., Professor of Pathology, Obstetrics and Gynecology, American board certified pathologist, graduated from Shanghai Medical College Fudan University and trained at Columbia University, Cornell University, and Brown University Medical Centers in anatomic pathology and gynecologic pathology, Selected by US News and World Report in 2013 as one of America's top pathologists, Dr. Zheng is an internationally recognized gynecologic pathologist with outstanding expertise in every aspect of gynecologic pathology. Dr. Zheng’s main research contributions include endometrial serous carcinogenesis and precancerous lesion endometrial glandular dysplasia, cell origin of low-grade ovarian serous carcinoma, hormonal etiology of ovarian epithelial cancers, and tubal contribution of ovarian endometriosis and its associated ovarian cancers.
- Medical School
- Shanghai Medical College of Fudan University (1982)
- Hospital of Obstetrics and Gynecology (1983), Obstetrics & Gynecology
- Hospital of Obstetrics and Gynecology (1986), Obstetrics & Gynecology
- Columbia University Medical Center (1989), Molecular Reproduction
- Cornell New York Presbyterian Hospital (1995), Pathology
- Brown University Woman & Infant Hospital (1996), Gynecologic Pathology
- Biomarkers to aid the diagnosis of gynecologic cancers
- Cervical cancer: suitable model of cervical cancer screening, effective intervention, and prevention in developing countries.
- Endometrial serous carcinoma: carcinogenesis, early detection and prevention
- Ovarian cancer early detection and prevention
- Tubal origin of ovarian endometriosis and its related cancer development
- Tubal secretory cell biology
- Association between human papillomavirus type 16 E6 and E7 variants with subsequent persistent infection and recurrence of cervical high-grade squamous intraepithelial lesion after conization.
- Zhang L, Yang B, Zhang A, Zhou A, Yuan J, Wang Y, Sun L, Cao H, Wang J, Zheng W J. Med. Virol. 2016 Apr
- Mechanism of progestin resistance in endometrial precancer/cancer through Nrf2-AKR1C1 pathway.
- Wang Y, Wang Y, Zhang Z, Park JY, Guo D, Liao H, Yi X, Zheng Y, Zhang D, Chambers SK, Zheng W Oncotarget 2016 Jan
- Fallopian tube secretory cell expansion: a sensitive biomarker for ovarian serous carcinogenesis.
- Wang Y, Li L, Wang Y, Tang SN, Zheng W Am J Transl Res 2016 8 1 230-8
- Overexpression and oncogenic function of HMGA2 in endometrial serous carcinogenesis.
- Wei L, Liu X, Zhang W, Wei Y, Li Y, Zhang Q, Dong R, Kwon JS, Liu Z, Zheng W, Kong B Am J Cancer Res 2016 6 2 249-59
- Cytologic studies of the fallopian tube in patients undergoing salpingo-oophorectomy.
- Chen H, Klein R, Arnold S, Chambers S, Zheng W Cancer Cell Int. 2016 16 78
- Ovarian serous carcinogenesis from tubal secretory cells.
- Zhang W, Wei L, Li L, Yang B, Kong B, Yao G, Zheng W Histol. Histopathol. 2015 Jul 11645
- Are clear cell carcinomas of the ovary and endometrium phenotypically identical? A proteomic analysis.
- Fata CR, Seeley EH, Desouki MM, Du L, Gwin K, Hanley KZ, Hecht JL, Jarboe EA, Liang SX, Parkash V, Quick CM, Zheng W, Shyr Y, Caprioli RM, Fadare O Hum. Pathol. 2015 Jun
- Primary sources of pelvic serous cancer in patients with endometrial intraepithelial carcinoma.
- Jia L, Yuan Z, Wang Y, Cragun JM, Kong B, Zheng W Mod. Pathol. 2015 Jan 28 1 118-27
- Tubal origin of ovarian endometriosis and clear cell and endometrioid carcinoma.
- Wang Y, Mang M, Wang Y, Wang L, Klein R, Kong B, Zheng W Am J Cancer Res 2015 5 3 869-79
- Flutamide and biomarkers in women at high risk for ovarian cancer: preclinical and clinical evidence.
- Gruessner C, Gruessner A, Glaser K, AbuShahin N, Zhou Y, Laughren C, Wright H, Pinkerton S, Yi X, Stoffer J, Azodi M, Zheng W, Chambers SK Cancer Prev Res (Phila) 2014 Sep 7 9 896-905